U.S. Genetic Testing Market Size, Share, Growth Analysis, By Application(Cardiology, Oncology, Pharmacogenomics, Cognitive Dysfunction), By Technique(PCR, DNA Sequencing, Microarrays, Others), By Region - Industry Forecast 2024-2031

The landscape reflects the presence of both established and up-and-coming players in the competitive setting. The two businesses Myriad Genetics and Quest Diagnostics that were the market leader. Due to its extensive genetic testing, Quest Diagnostics dominates the market portfolio with a variety of application areas, including autoimmune disorders, different disorders, as well as heart problems. Due to its existence, Myriad Genetics is anticipated to be the second largest firm in terms of market revenue share in technologically sophisticated goods. Some of Myriad's well-known product lines, EndoPredict and MyRisk are examples of genetics. In other businesses like BioReference, Ambry Genetics, and Invitae Corporation, the goal of laboratories is to keep their position supported by innovative product offerings. Strong investment activities are expected to support R&D endeavors to lead to the emergence of new players

Top Players in the Global US Genetic Testing Market

• 23andMe
• AncestryDNA
• Invitae Corporation
• Quest Diagnostics
• Myriad Genetics
• Illumina, Inc.
• GeneDx
• Ambry Genetics
• BGI Group
• Blueprint Genetics
• Counsyl, Inc.
• Natera, Inc.
• Roche Diagnostics
• Genomic Health
• Guardant Health
• Helix OpCo LLC
• Opko Health
• Thermo Fisher Scientific
• Veracyte
• Fulgent Genetics

US Genetic Testing Market Recent Development

• April 2021 – Invitae Corporation announced that their sponsored genetic testing is available for patients at risk of developing some common adult neurodegenerative conditions in the region of US, Canada, Australia, and Brazil. This availability of this program will be free of cost and will help at-risk individuals having difficulty diagnosing conditions
• April 2021 – Invitae Corporation announced that they will join the eMERGE network, a national effort organized and funded by National Genome Research Institute. As a part of this partnership, Invitae will provide genetic testing for all 25,000 patients.
• March 2021 – GI OnDemand announced a partnership with Ambry Genetics to integrate the online genetic counseling and testing services into their nationwide gastroenterology practices. The partnership was made to identify hereditary GI cancer syndromes to guide through potentially life-altering healthcare decisions.